Oncolytics Biotech (ONC) Stock Price, News & Analysis

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Key Stats

• Today's Range: C$14.90 to C$14.90
• 50-Day Range: C$14.90 to C$14.90
• 52-Week Range: C$0.44 to C$2.08
• Volume: 280 shs
• Average Volume: 169,589 shs
• Market Capitalization: C$1.50 billion
• P/E Ratio: N/A
• Dividend Yield: 0.31%
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/12/2024
• Today: 9/03/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: TSE:ONC
• CIK: N/A
• Web: www.oncolyticsbiotech.com
• Phone: +1-403-6707380
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$27.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -204.28%
• Return on Assets: -71.33%

Debt

• Debt-to-Equity Ratio: 14.58
• Current Ratio: 2.88
• Quick Ratio: 8.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$3.53 per share
• Price / Cash Flow: 4.22
• Book Value: C$0.07 per share
• Price / Book: 222.68

Miscellaneous

• Outstanding Shares: 100,361,000
• Free Float: N/A
• Market Cap: C$1.50 billion
• Optionable: Not Optionable
• Beta: 0.80